On December 4, 2023, Absci, a leader in generative AI antibody discovery, announced a collaboration with AstraZeneca, a global biopharmaceutical company, to deliver an AI-designed antibody against an oncology target. Wilson Sonsini Goodrich & Rosati advised Absci on the transaction.

The collaboration combines Absci's Integrated Drug Creation™ platform with AstraZeneca's expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate. Absci will contribute its pioneering generative AI technology to deliver a therapeutic candidate antibody for a specified oncology target. The agreement includes an upfront commitment, R&D funding, and milestone payments, in addition to royalties on product sales.

The Wilson Sonsini team that advised Absci on the transaction included Ian Edvalson, David Pirko, Miruna Predescu, and Jason Xu.

For more information, please see Absci's news release. Additional coverage can be found on Financial Times, Reuters, and AI News.